Addiction

For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...

Presented by Richard Rawson, PhD, Emeritus Professor in the Department of Psychiatry and Biobehavioral Science, UCLA School of Medicine and a Research Professor at the University of Vermont, this presentation provided an overview of the...

In the magazine CIJ Informa, the participation of CIJ, host chapter institution of ISSUP Mexico, in the 71st Regular Session of CICAD is reviewed.

Abstract Objective The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration–approved medications for treatment of opioid use disorder: methadone, buprenorphine, and...

Key Points Question What treatments for cocaine use disorder are associated with objective reductions in cocaine use among adults? Findings In this meta-analysis of 157 clinical trials comprising 402 treatment groups and 15 842 participants...

Cocaine is an addictive stimulant drug that originates from the leaves of the coca plant, which is indigenous to South America. The drug's effects include heightened alertness, attention, and energy, as well as feelings of euphoria and...